Using Prazosin to help treat alcohol use disorder and withdrawal symptoms
Prazosin Treatment for Alcohol Use Disorder with Alcohol Withdrawal Symptoms
This study is looking at whether the medication Prazosin can help people with Alcohol Use Disorder who are going through withdrawal, by comparing its effects to a placebo over 12 weeks, and it’s open to anyone who wants to see if this treatment can make a difference in their recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11042721 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of Prazosin, a medication typically used for high blood pressure, in treating individuals with Alcohol Use Disorder (AUD) who are experiencing alcohol withdrawal symptoms. The study will involve a 12-week clinical trial with 150 participants, where half will receive Prazosin and the other half a placebo. Researchers will monitor changes in alcohol consumption, cravings, anxiety, and overall health during and after the treatment period. The goal is to determine if Prazosin can improve outcomes for those struggling with AUD and withdrawal symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults seeking treatment for alcohol use disorder who are also experiencing three or more withdrawal symptoms.
Not a fit: Patients who do not have alcohol use disorder or who are not experiencing withdrawal symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with alcohol use disorder, particularly those experiencing withdrawal symptoms.
How similar studies have performed: Previous research has shown that medications targeting withdrawal symptoms can improve treatment outcomes for alcohol use disorder, suggesting potential success for this approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Sinha, Rajita — Yale University
- Study coordinator: Sinha, Rajita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.